-
2025 HDBuzz Prize: ACTing on HD: Exploring Acceptance and Commitment Therapy to Improve Mental Health in People with Huntington’s Disease and Their Caregiver
Latest News
-
2025 HDBuzz Prize: Calm Before the Storm: Early Clues of Huntington’s Disease Found in Brainwaves
We’re proud to announce Eva Woods as a 2025 HDBuzz Prize winner! Scientists spotted small brainwave changes in people with HD before symptoms begin. These early electrical “whispers” of HD could help track effects years before diagnosis.
-
Youthful competitors: young brain cells oust the old
Replacing cells with HD in the brain could be an effective treatment strategy. Recent work shows that glia injected into mouse brains take over and oust the older cells, but for a surprising reason – because of age, not HD!
-
Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
Both PTC Therapeutics and uniQure have shared updates from their respective clinical trials, testing different huntingtin-lowering approaches. We explore the data presented from both of these studies and what this means for HD family members.
-
Huntington’s disease therapeutics conference 2023 – Day 3
Check out research updates from Day 3 of the 2022 HD Therapeutics Conference #HDTC2023
-
Huntington’s disease therapeutics conference 2023 – Day 2
Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2023
-
Huntington’s disease therapeutics conference 2023 – Day 1
Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2023
-
PROOF-HD study of pridopidine ends with negative result
The phase 3 trial missed its primary endpoint of slowing loss of function in Huntington’s disease
-
Astrocytes: The new star in HD research?
A new article summarizes what the Huntington's disease field has found about a type of brain cell called an astrocyte. These star-shaped cells help keep brain cells healthy and could be leveraged for developing new HD therapeutics.
-
Hunting for balance: how the huntingtin protein compensates in HD
Researchers look at the cause and effect of various forms of the HTT protein. They find both expanded and unexpanded HTT contribute to brain cell communication and the brain has an amazing capacity to compensate for changes related to disease
-
Roche Phase II GENERATION HD2 study underway
Roche released a community letter in early 2023, to share that their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. In this article, we summarise the latest news about this huntingtin-lowering drug.
-
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
Novartis have announced that they are ending development of the drug branaplam in Huntington’s disease. Here, we review this latest news and its impact on the HD community.